MedTrace Logo

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

NCT06547216 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-05-14

No results posted yet for this study

Summary

A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Conditions

  • FSHD
  • FSHD1
  • FSHD2
  • FMD
  • FMD2
  • Fascioscapulohumeral Muscular Dystrophy
  • Fascioscapulohumeral Muscular Dystrophy Type 1
  • Fascioscapulohumeral Muscular Dystrophy Type 2
  • Dystrophies, Facioscapulohumeral Muscular
  • Dystrophy, Facioscapulohumeral Muscular
  • Facioscapulohumeral Muscular Dystrophy 1
  • Facioscapulohumeral Muscular Dystrophy 2
  • Facio-Scapulo-Humeral Dystrophy
  • Atrophy, Facioscapulohumeral
  • Atrophies, Facioscapulohumeral
  • Facioscapulohumeral Atrophy
  • Muscular Dystrophies
  • Muscular Dystrophy, Facioscapulohumeral
  • FSH Muscular Dystrophy
  • Landouzy Dejerine Dystrophy
  • Landouzy-Dejerine Muscular Dystrophy
  • Dystrophies, Landouzy-Dejerine
  • Dystrophy, Landouzy-Dejerine
  • Landouzy-Dejerine Syndrome
  • Muscular Dystrophy, Landouzy Dejerine
  • Progressive Muscular Dystrophy
  • FSH

Interventions

DRUG

AOC 1020

AOC 1020 will be administered via intravenous (IV) infusion

Sponsors & Collaborators

  • Avidity Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-25
Primary Completion
2030-04-30
Completion
2030-06-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547216 on ClinicalTrials.gov